Symbols / JSPR Stock $0.91 -3.42% Jasper Therapeutics, Inc.
JSPR (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factors from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma. Jasper Therapeutics, Inc. was founded in 2018 and is headquartered in Redwood City, California.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-01 | main | Evercore ISI Group | Outperform → Outperform | $7 |
| 2025-11-11 | main | RBC Capital | Sector Perform → Sector Perform | $4 |
| 2025-09-22 | main | Evercore ISI Group | Outperform → Outperform | $14 |
| 2025-09-22 | main | JMP Securities | Market Outperform → Market Outperform | $6 |
| 2025-09-22 | main | BTIG | Buy → Buy | $7 |
| 2025-08-15 | main | UBS | Buy → Buy | $25 |
| 2025-07-08 | down | BMO Capital | Outperform → Market Perform | $4 |
| 2025-07-08 | main | JMP Securities | Market Outperform → Market Outperform | $12 |
| 2025-07-08 | main | Evercore ISI Group | Outperform → Outperform | $20 |
| 2025-07-07 | down | William Blair | Outperform → Market Perform | — |
| 2025-07-07 | main | HC Wainwright & Co. | Buy → Buy | $20 |
| 2025-07-07 | down | Cantor Fitzgerald | Overweight → Neutral | — |
| 2025-07-07 | main | BTIG | Buy → Buy | $20 |
| 2025-05-15 | main | Oppenheimer | Outperform → Outperform | $65 |
| 2025-05-13 | main | UBS | Buy → Buy | $33 |
| 2025-03-11 | reit | HC Wainwright & Co. | Buy → Buy | $40 |
| 2025-02-13 | init | UBS | — → Buy | $38 |
| 2025-01-10 | reit | JMP Securities | Market Outperform → Market Outperform | $70 |
| 2025-01-10 | main | HC Wainwright & Co. | Buy → Buy | $40 |
| 2025-01-09 | main | RBC Capital | Outperform → Outperform | $48 |
- Morgan Stanley units report sub‑5% stakes in Jasper Therapeutics (JSPR) - Stock Titan ue, 12 May 2026 16
- Evercore ISI Lowers its Price Target on Jasper Therapeutics (JSPR) to $7 - Yahoo Finance ue, 07 Apr 2026 07
- $JSPR stock is up 22% today. Here's what we see in our data. - Quiver Quantitative ue, 02 Dec 2025 08
- Citizens reiterates Jasper Therapeutics stock rating on CEO change - Investing.com Wed, 01 Apr 2026 07
- TradingKey - TradingKey ue, 12 May 2026 09
- Goldman Sachs (JSPR) joint 13G/A: 128,862 shares, 0.5% stake - Stock Titan Fri, 08 May 2026 17
- Jasper’s Stock Is In The Basement, But The Bet Is Binary - Finimize hu, 04 Dec 2025 08
- Companies Like Jasper Therapeutics (NASDAQ:JSPR) Could Be Quite Risky - simplywall.st hu, 08 Jan 2026 08
- Companies Like Jasper Therapeutics (NASDAQ:JSPR) Could Be Quite Risky - Yahoo Finance hu, 20 Nov 2025 08
- Soleus entities show combined 1.0% stake in Jasper Therapeutics (NASDAQ: JSPR) - Stock Titan Fri, 08 May 2026 21
- Jasper Therapeutics Slides As Insider Purchases Lose Another US$89k - simplywall.st Wed, 05 Nov 2025 08
- Jasper Therapeutics stock rises after leadership changes - Investing.com Wed, 07 Jan 2026 08
- Why UBS Started Jasper Therapeutics (JSPR) at Neutral Despite Progress in Briquilimab - Yahoo Finance Sun, 29 Mar 2026 07
- Jasper targets late-2026 trial after 75% disease-control data - Stock Titan Mon, 30 Mar 2026 07
- Jasper Therapeutics stock maintains Market Outperform rating at Citizens - Investing.com Wed, 03 Dec 2025 08
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
83.88
+10.03%
|
76.24
+10.71%
|
68.86
+34.50%
|
51.20
|
| Research And Development |
|
63.10
+13.05%
|
55.82
+7.79%
|
51.78
+49.55%
|
34.63
|
| Selling General And Administration |
|
20.78
+1.77%
|
20.42
+19.57%
|
17.08
+3.06%
|
16.57
|
| General And Administrative Expense |
|
20.78
+1.77%
|
20.42
+19.57%
|
17.08
+3.06%
|
16.57
|
| Other Gand A |
|
20.78
+1.77%
|
20.42
+19.57%
|
17.08
+3.06%
|
16.57
|
| Total Expenses |
|
83.88
+10.03%
|
76.24
+10.71%
|
68.86
+34.50%
|
51.20
|
| Operating Income |
|
-83.88
-10.03%
|
-76.24
-10.71%
|
-68.86
-34.50%
|
-51.20
|
| Total Operating Income As Reported |
|
-83.88
-10.03%
|
-76.24
-10.71%
|
-68.86
-34.50%
|
-51.20
|
| EBITDA |
|
-82.83
-10.63%
|
-74.87
-10.50%
|
-67.75
-34.91%
|
-50.22
|
| Normalized EBITDA |
|
-91.36
-22.02%
|
-74.87
-11.41%
|
-67.20
-6.41%
|
-63.15
|
| Reconciled Depreciation |
|
1.06
-23.09%
|
1.37
+23.92%
|
1.11
+13.64%
|
0.97
|
| EBIT |
|
-83.88
-10.03%
|
-76.24
-10.71%
|
-68.86
-34.50%
|
-51.20
|
| Total Unusual Items |
|
8.53
|
0.00
+100.00%
|
-0.56
-104.31%
|
12.93
|
| Total Unusual Items Excluding Goodwill |
|
8.53
|
0.00
+100.00%
|
-0.56
-104.31%
|
12.93
|
| Special Income Charges |
|
—
|
0.00
-100.00%
|
0.02
-99.69%
|
5.72
|
| Restructuring And Mergern Acquisition |
|
—
|
0.00
+100.00%
|
-0.02
+99.69%
|
-5.72
|
| Net Income |
|
-75.80
-6.36%
|
-71.27
-10.55%
|
-64.47
-71.06%
|
-37.69
|
| Pretax Income |
|
-75.80
-6.36%
|
-71.27
-10.55%
|
-64.47
-71.06%
|
-37.69
|
| Net Non Operating Interest Income Expense |
|
1.74
-65.58%
|
5.06
-2.71%
|
5.20
+641.65%
|
0.70
|
| Net Interest Income |
|
1.74
-65.58%
|
5.06
-2.71%
|
5.20
+641.65%
|
0.70
|
| Interest Income Non Operating |
|
1.74
-65.58%
|
5.06
-2.71%
|
5.20
+641.65%
|
0.70
|
| Interest Income |
|
1.74
-65.58%
|
5.06
-2.71%
|
5.20
+641.65%
|
0.70
|
| Other Income Expense |
|
6.34
+7305.68%
|
-0.09
+89.04%
|
-0.80
-106.27%
|
12.81
|
| Other Non Operating Income Expenses |
|
-2.19
-2385.23%
|
-0.09
+64.23%
|
-0.25
-113.91%
|
-0.12
|
| Gain On Sale Of Security |
|
8.53
|
—
|
-0.57
-107.99%
|
7.20
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-75.80
-6.36%
|
-71.27
-10.55%
|
-64.47
-71.06%
|
-37.69
|
| Net Income From Continuing Operation Net Minority Interest |
|
-75.80
-6.36%
|
-71.27
-10.55%
|
-64.47
-71.06%
|
-37.69
|
| Net Income From Continuing And Discontinued Operation |
|
-75.80
-6.36%
|
-71.27
-10.55%
|
-64.47
-71.06%
|
-37.69
|
| Net Income Continuous Operations |
|
-75.80
-6.36%
|
-71.27
-10.55%
|
-64.47
-71.06%
|
-37.69
|
| Normalized Income |
|
-84.33
-18.32%
|
-71.27
-11.52%
|
-63.91
-26.28%
|
-50.61
|
| Net Income Common Stockholders |
|
-75.80
-6.36%
|
-71.27
-10.55%
|
-64.47
-71.06%
|
-37.69
|
| Diluted EPS |
|
—
|
-4.89
+20.87%
|
-6.18
+40.00%
|
-10.30
|
| Basic EPS |
|
—
|
-4.89
+20.87%
|
-6.18
+40.00%
|
-10.30
|
| Basic Average Shares |
|
—
|
14.58
+39.71%
|
10.44
+186.14%
|
3.65
|
| Diluted Average Shares |
|
—
|
14.58
+39.71%
|
10.44
+186.14%
|
3.65
|
| Diluted NI Availto Com Stockholders |
|
-75.80
-6.36%
|
-71.27
-10.55%
|
-64.47
-71.06%
|
-37.69
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
94.89
|
| Current Assets |
|
88.94
|
| Cash Cash Equivalents And Short Term Investments |
|
86.89
|
| Cash And Cash Equivalents |
|
86.89
|
| Receivables |
|
0.25
|
| Other Receivables |
|
—
|
| Taxes Receivable |
|
0.25
|
| Prepaid Assets |
|
1.51
|
| Other Current Assets |
|
0.29
|
| Total Non Current Assets |
|
5.95
|
| Net PPE |
|
4.19
|
| Gross PPE |
|
6.65
|
| Accumulated Depreciation |
|
-2.46
|
| Properties |
|
0.00
|
| Machinery Furniture Equipment |
|
0.74
|
| Other Properties |
|
3.44
|
| Leases |
|
2.48
|
| Other Non Current Assets |
|
1.76
|
| Total Liabilities Net Minority Interest |
|
16.45
|
| Current Liabilities |
|
12.37
|
| Payables And Accrued Expenses |
|
9.32
|
| Payables |
|
4.15
|
| Accounts Payable |
|
4.15
|
| Current Accrued Expenses |
|
5.17
|
| Employee Benefits |
|
0.00
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
1.77
|
| Current Debt And Capital Lease Obligation |
|
0.97
|
| Current Capital Lease Obligation |
|
0.97
|
| Other Current Liabilities |
|
0.32
|
| Total Non Current Liabilities Net Minority Interest |
|
4.08
|
| Long Term Debt And Capital Lease Obligation |
|
1.81
|
| Long Term Capital Lease Obligation |
|
1.81
|
| Long Term Provisions |
|
—
|
| Tradeand Other Payables Non Current |
|
—
|
| Other Non Current Liabilities |
|
2.26
|
| Preferred Securities Outside Stock Equity |
|
—
|
| Stockholders Equity |
|
78.44
|
| Common Stock Equity |
|
78.44
|
| Capital Stock |
|
0.00
|
| Common Stock |
|
0.00
|
| Preferred Stock |
|
0.00
|
| Share Issued |
|
11.16
|
| Ordinary Shares Number |
|
11.16
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
248.04
|
| Retained Earnings |
|
-169.60
|
| Total Equity Gross Minority Interest |
|
78.44
|
| Total Capitalization |
|
78.44
|
| Working Capital |
|
76.56
|
| Invested Capital |
|
78.44
|
| Total Debt |
|
2.79
|
| Capital Lease Obligations |
|
2.79
|
| Net Tangible Assets |
|
78.44
|
| Tangible Book Value |
|
78.44
|
| Derivative Product Liabilities |
|
0.00
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-77.16
-23.26%
|
-62.60
-20.23%
|
-52.07
-13.54%
|
-45.86
|
| Cash Flow From Continuing Operating Activities |
|
-77.16
-23.26%
|
-62.60
-20.23%
|
-52.07
-13.54%
|
-45.86
|
| Net Income From Continuing Operations |
|
-75.80
-6.36%
|
-71.27
-10.55%
|
-64.47
-71.06%
|
-37.69
|
| Depreciation Amortization Depletion |
|
1.06
-23.09%
|
1.37
+23.92%
|
1.11
+13.64%
|
0.97
|
| Depreciation And Amortization |
|
1.06
-23.09%
|
1.37
+23.92%
|
1.11
+13.64%
|
0.97
|
| Other Non Cash Items |
|
-5.32
-1183.10%
|
0.49
+22.44%
|
0.40
+107.44%
|
-5.39
|
| Stock Based Compensation |
|
6.71
+1.42%
|
6.62
+27.02%
|
5.21
+27.38%
|
4.09
|
| Asset Impairment Charge |
|
1.11
|
0.00
|
—
|
—
|
| Operating Gains Losses |
|
—
|
0.01
-98.09%
|
0.57
+107.99%
|
-7.20
|
| Gain Loss On Investment Securities |
|
—
|
—
|
0.57
+107.99%
|
-7.20
|
| Gain Loss On Sale Of PPE |
|
—
|
0.01
|
0.00
|
—
|
| Change In Working Capital |
|
-4.92
-2775.54%
|
0.18
-96.39%
|
5.10
+886.29%
|
-0.65
|
| Change In Receivables |
|
—
|
0.00
-100.00%
|
0.66
+200.00%
|
-0.66
|
| Change In Prepaid Assets |
|
-1.78
+16.20%
|
-2.12
-376.79%
|
0.77
+145.83%
|
0.31
|
| Change In Payables And Accrued Expense |
|
-2.18
-179.11%
|
2.76
-47.00%
|
5.20
+495.59%
|
-1.31
|
| Change In Accrued Expense |
|
-4.37
-251.93%
|
2.88
+2.06%
|
2.82
+237.44%
|
0.84
|
| Change In Payable |
|
2.19
+1897.54%
|
-0.12
-105.12%
|
2.38
+210.69%
|
-2.15
|
| Change In Account Payable |
|
2.19
+1897.54%
|
-0.12
-105.12%
|
2.38
+210.69%
|
-2.15
|
| Change In Other Current Assets |
|
0.71
+35.18%
|
0.52
+189.55%
|
-0.58
-412.28%
|
-0.11
|
| Change In Other Current Liabilities |
|
-1.67
-71.63%
|
-0.97
-2.96%
|
-0.94
-183.55%
|
1.13
|
| Investing Cash Flow |
|
0.01
+100.94%
|
-0.53
-99.25%
|
-0.27
+53.65%
|
-0.58
|
| Cash Flow From Continuing Investing Activities |
|
0.01
+100.94%
|
-0.53
-99.25%
|
-0.27
+53.65%
|
-0.58
|
| Net PPE Purchase And Sale |
|
0.01
+100.94%
|
-0.53
-99.25%
|
-0.27
+53.65%
|
-0.58
|
| Purchase Of PPE |
|
-0.01
+98.73%
|
-0.55
-106.74%
|
-0.27
+53.65%
|
-0.58
|
| Sale Of PPE |
|
0.01
-40.00%
|
0.02
|
0.00
|
—
|
| Capital Expenditure |
|
-0.01
+98.73%
|
-0.55
-106.74%
|
-0.27
+53.65%
|
-0.58
|
| Financing Cash Flow |
|
34.21
-28.55%
|
47.88
-52.58%
|
100.97
+183483.64%
|
0.06
|
| Cash Flow From Continuing Financing Activities |
|
34.21
-28.55%
|
47.88
-52.58%
|
100.97
+183483.64%
|
0.06
|
| Net Common Stock Issuance |
|
33.97
-28.03%
|
47.20
-53.49%
|
101.48
|
0.00
|
| Proceeds From Stock Option Exercised |
|
0.24
-64.73%
|
0.69
+52.43%
|
0.45
+721.82%
|
0.06
|
| Net Other Financing Charges |
|
—
|
—
|
-0.96
|
—
|
| Changes In Cash |
|
-42.95
-181.61%
|
-15.25
-131.35%
|
48.64
+204.87%
|
-46.38
|
| Beginning Cash Position |
|
72.05
-17.47%
|
87.30
+125.78%
|
38.67
-54.53%
|
85.05
|
| End Cash Position |
|
29.11
-59.60%
|
72.05
-17.47%
|
87.30
+125.78%
|
38.67
|
| Free Cash Flow |
|
-77.17
-22.19%
|
-63.15
-20.67%
|
-52.33
-12.71%
|
-46.43
|
| Common Stock Issuance |
|
33.97
-28.03%
|
47.20
-53.49%
|
101.48
|
0.00
|
| Issuance Of Capital Stock |
|
33.97
-28.03%
|
47.20
-53.49%
|
101.48
|
0.00
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-03-30 View
- 10-K2026-03-30 View
- 42026-02-10 View
- 8-K2026-01-08 View
- 8-K2026-01-07 View
- 42026-01-05 View
- 42026-01-05 View
- 42026-01-05 View
- 8-K2025-12-02 View
- 10-Q2025-11-10 View
- 8-K2025-11-10 View
- 42025-09-24 View
- 42025-09-24 View
- 42025-09-24 View
- 42025-09-24 View
- 8-K2025-09-19 View
- 8-K2025-08-13 View
- 10-Q2025-08-13 View
- 8-K2025-07-09 View
- 8-K2025-07-07 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|